News
Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...
Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...
Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...
Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.
Soy Nómada on MSN1h
Medicare and Medicaid Could Start Covering Anti-Obesity Drugs
A groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under ...
China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...
Fashion Glamp on MSN6h
A Pivotal Advance in Obesity Treatment: Eli Lilly's Oral Pill Shows Significant Weight Loss in Landmark Trial
A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...
Kantar’s report highlights the growing importance of personalised and functional wellness solutions, says Soumya Mohanty, MD ...
Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...
Researchers have found a potential game-changing way to help people lose weight and control blood sugar without the unpleasant side effects of today’s popular drugs like Ozempic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback